AIMDW / Ainos, Inc. - Equity Warrant - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Ainos, Inc. - ضمان حقوق الملكية

الإحصائيات الأساسية
LEI 549300AX97HS3UDQ2Y10
CIK 1014763
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ainos, Inc. - Equity Warrant
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
September 5, 2025 424B5

AINOS, INC. Up to $874,496 of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-279880 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 11, 2024 and the Prospectus Supplement dated July 11, 2024) AINOS, INC. Up to $874,496 of Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated July 11, 2024, and its accompanying prospectus dated June 11

August 13, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

August 13, 2025 EX-99.1

Ainos Reports Second Quarter 2025 Financial Results

Exhibit 99.1 Ainos Reports Second Quarter 2025 Financial Results 1H 2025 Kicks Off AI Nose’s Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships AI Nose 90-Day Roadmap to Power 2H 2025, With First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing SAN DIEGO, CA/ ACCESSWIRE/ August 13, 2025/ Ainos, Inc. (NASDAQ:AIMD)(NA

August 13, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-41461 AINOS, INC. (Ex

August 7, 2025 EX-99.1

Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting

Exhibit 99.1 Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial Applications Ainos Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan San Diego, CA – August 6, 2025 – Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“A

August 7, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

July 31, 2025 EX-16.1

Letter from KCCW Accountancy Corp.

Exhibit 16.1 July 31, 2025 Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, D.C. 20549 Re: Ainos, Inc. Dear Sir or Madam: We have read the statements under item 4.01 in the Form 8-K dated July 31, 2025, of Ainos, Inc. (the “Company”), and we agree with such statements therein as related to our firm. We have no basis to, and therefore, do not agree or d

July 31, 2025 8-K

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

July 16, 2025 EX-99.1

Ainos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026

Exhibit 99.1 Ainos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026 Commercial Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”), a pioneer in AI-powered scent digitization, today a

July 16, 2025 8-K

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

July 1, 2025 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

July 1, 2025 EX-3.1

Certificate of Amendment to the Restated Certificate of Formation of Ainos, Inc., as filed with the Texas Secretary of State on June 6, 2025

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF FORMATION OF AINOS, INC. Pursuant to the Texas Business Organizations Code (the “Code”), the undersigned adopts the following Certificate of Amendment to its Restated Certificate of Formation, dated April 15, 2021, as amended (the “Certificate of Formation”). The name of the filing entity is Ainos, Inc. (the “Corporation”). This d

June 24, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

June 24, 2025 EX-99.1

Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia

Exhibit 99.1 Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia AI Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environmental sensing markets Kenmec and Ainos to show case AI Nose and SLM in Automation Taipei 2025 in August SAN DIEGO, CA – June 24, 2025 – Ainos, Inc. (NASDAQ: AIMD, AIMDW)

May 29, 2025 DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☒ Definitive Information Statement AINOS, INC. (Name of Registrant

May 19, 2025 PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☐ Definitive Information Statement AINOS, INC. (Name of Registrant

May 14, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-41461 AINOS, INC. (E

May 12, 2025 EX-99.1

Ainos Reports First Quarter 2025 Financial Results

Exhibit 99.1 Ainos Reports First Quarter 2025 Financial Results Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DI

May 12, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

April 4, 2025 S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact Name of Registrant as Specified in Its Charter) TEXAS 75-1974352 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8880 Rio San Diego Drive, Ste. 800 San Diego, CA (858) 869-2986 92108 (Address

April 4, 2025 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) AINOS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regi

March 14, 2025 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

March 14, 2025 EX-10.1

Amendment to Convertible Promissory Note, dated March 12, 2025, by and between Ainos, Inc. and Li-Kuo Lee.

Exhibit 10.1 AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This AMENDMENT TO CONVERTIBLE PROMISSORY NOTE (the “Amendment”) is made and executed as of March 12, 2025, by and between Li-Kuo Lee (the “Purchaser” or “Holder”) and Ainos, Inc., a Texas corporation (the “Company”). Background A. On March 13, 2023, the Company executed and delivered to Purchaser a convertible promissory note (the “Note”) in th

March 11, 2025 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

March 11, 2025 EX-99.1

Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

Exhibit 99.1 Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire / March 11, 2025 / Ainos, Inc. (NASDAQ: AIMD, NASDAQ: AIMDW) (“Ainos” or the “Company”), a leader in AI-driven scent digitization, has announced a strategic collaboration with Adv

March 11, 2025 EX-10.1

Amendment to Convertible Promissory Note, dated March 10, 2025, by and between Ainos, Inc. and ASE Test, Inc.

Exhibit 10.1 AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This AMENDMENT TO CONVERTIBLE PROMISSORY NOTE (the “Amendment”) is made and executed as of March 10, 2025, by and between ASE Test, Inc., corporation limited by shares incorporated in Taiwan, the Public of China (the “Purchaser” or “Holder”) and Ainos, Inc., a Texas corporation (the “Company”). Background A. On March 13, 2023, the Company execu

March 11, 2025 8-K

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

March 7, 2025 8-K

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

March 7, 2025 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2024 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-41461 AINOS, INC. (Exact name of regist

March 7, 2025 EX-99.1

Ainos Reports Full Year 2024 Financial Results

Exhibit 99.1 Ainos Reports Full Year 2024 Financial Results Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren’s syndrome clinical study SAN DIEGO, CA / ACCESSWIRE /March 07, 2025 /

March 7, 2025 EX-4.7

Description of securities

EXHIBIT 4.7 DESCRIPTION OF SECURITIES Ainos, Inc. (the “Company,” “we,” “us” or “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share, and warrants to purchase common stock (the “Warrants”). General Our authorized capital stock consists of 300,000,000 shares of common sto

March 7, 2025 EX-24.1

Power of Attorney

EXHIBIT 24.1 AINOS, INC. POWER OF ATTORNEY WHEREAS, AINOS, INC., a Texas corporation (hereinafter referred to as the “Company”), proposes to file with the Securities and Exchange Commission under the provisions of the Securities Exchange Act of 1934, as amended, an annual report on Form 10-K for the period ending December 31, 2024 (the “Form 10-K”). NOW, THEREFORE, the undersigned members of the B

March 5, 2025 8-K

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

March 5, 2025 EX-99.1

Ainos and ugo to Develop the World’s First Robot with a Sense of Smell

Exhibit 99.1 Ainos and ugo to Develop the World’s First Robot with a Sense of Smell A Major Breakthrough in Ainos’ Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswire / March 05, 2025 / Ainos, Inc. (Nasdaq: AIMD, AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan’s larg

December 30, 2024 S-3/A

As filed with the Securities and Exchange Commission on December 30, 2024

As filed with the Securities and Exchange Commission on December 30, 2024 Registration No.

December 30, 2024 CORRESP

AINOS, INC. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

AINOS, INC. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 December 30, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, DC 20549 Re: Ainos, Inc. Registration Statement on Form S-3, File No. 333-284003 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: December 31, 2024 Requested Time: 4:30

December 23, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ainos, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa

December 23, 2024 S-3

As filed with the Securities and Exchange Commission on December 20, 2024

As filed with the Securities and Exchange Commission on December 20, 2024 Registration No.

December 4, 2024 EX-99.1

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren’s Syndrome Drug

Exhibit 99.1 Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren’s Syndrome Drug San Diego, California—(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) (“Ainos” or the “Company”), an innovative healthcare company focused on advanced AI-driven point-of-care testing (“POCT”) and low-dos

December 4, 2024 8-K

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number)

November 27, 2024 SC 13D/A

AIMD / Ainos, Inc. / AINOS INC Activist Investment

SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Ainos, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhua

November 6, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-41461 AINOS, INC

October 22, 2024 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number)

October 22, 2024 EX-10.1

English Translation of Third Addendum to Product Development Agreement, dated October 16, 2024

Exhibit 10.1 This is the English translation of the Chinese version. In case of discrepancies between Chinese and English versions, the Chinese version shall prevail. Third Addendum to the Product Development Agreement Taiwan Carbon Nano Technology Corporation (hereinafter referred to as Party A) and Ainos, Inc., its subsidiaries and branch offices (hereinafter referred to as Party B), on August 1

October 1, 2024 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number

August 21, 2024 SC 13D

AIMD / Ainos, Inc. / Taiwan Carbon Nano Technology Corp Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ainos, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District New Taipei City

August 20, 2024 SC 13D/A

AIMD / Ainos, Inc. / AINOS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Ainos, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District New Taipei Cit

August 20, 2024 EX-1

Voting Agreement, dated August 15, 2024, between Ainos, Inc. and Taiwan Carbon Nano Technology Corporation

EX-1 2 ex1.htm Exhibit 1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is dated as of August 15, 2024, by and among AINOS INC., a Cayman Islands company (“Ainos KY”), and the individuals and entities listed on Schedule A hereto (each a “Stockholder” and together the “Stockholders”). WHEREAS each Stockholder is a stockholder of Ainos, Inc., a Texas corporation (the “Company”); WHEREAS t

August 16, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

August 15, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

August 9, 2024 EX-10.1

Patent License Agreement, dated August 6, 2024, by and between Ainos, Inc. and Taiwan Carbon Nano Technology Corporation.

Exhibit 10.1 Patent License Agreement This Patent License Agreement (this “Agreement”) is made and entered into as of the Effective Date of August 6, 2024, in two original counterparts, by and between Taiwan Carbon Nano Technology Corporation (“LICENSOR”), a Taiwan company having an office and place of business at 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.) an

August 9, 2024 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

August 5, 2024 8-K

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

August 5, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-41461 AINOS, INC. (Ex

August 5, 2024 EX-99.1

Ainos Reports Second Quarter 2024 Financial Results

Exhibit 99.1 Ainos Reports Second Quarter 2024 Financial Results Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developments Robust financial runway for over 12 months following the prepayment of a senior secured convertible note SAN DIEGO, CA / ACCESSWIRE /August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (“Ainos”, or the “Company”),

July 22, 2024 S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact Name of Registrant as Specified in Its Charter) TEXAS 75-1974352 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8880 Rio San Diego Drive, Ste. 800 San Diego, CA (858) 869-2986 92108 (Address

July 22, 2024 S-8 POS

As filed with the U.S. Securities and Exchange Commission on July 19, 2024

As filed with the U.S. Securities and Exchange Commission on July 19, 2024 Registration Statement No. 333-266043 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact name of registrant as specified in its charter) TEXAS 75-1974352 (State or other jurisdiction of

July 22, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) AINOS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regi

July 22, 2024 S-8 POS

As filed with the U.S. Securities and Exchange Commission on July 19, 2024

As filed with the U.S. Securities and Exchange Commission on July 19, 2024 Registration Statement No. 333-272639 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact name of registrant as specified in its charter) TEXAS 75-1974352 (State or other jurisdiction of

July 19, 2024 8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

July 12, 2024 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

July 12, 2024 EX-10.1

English Translation of Second Addendum to Product Development Agreement, dated July 8, 2024

Exhibit 10.1 This is the English translation of the Chinese version. In case of discrepancies between Chinese and English versions, the Chinese version shall prevail. Second Addendum to the Product Development Agreement Taiwan Carbon Nano Technology Corporation (hereinafter referred to as Party A) and Ainos, Inc., its subsidiaries and branch offices (hereinafter referred to as Party B), on August

July 11, 2024 424B5

AINOS, INC.

Filed pursuant to Rule 424(b)(5) Registration No. 333-279880 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 11, 2024) AINOS, INC. $1,840,350 This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated June 11, 2024, and its accompanying prospectus dated June 11, 2024 (collectively, the “June 11th Prospectus”), relating to the off

June 20, 2024 EX-99.1

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Exhibit 99.1 Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen product targeting at-home testing Next-Gen Ainos Flora will advance with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kicko

June 20, 2024 EX-3.1

Amended and Restated Bylaws of Ainos, Inc.

Exhibit 3.1 AINOS, INC. AMENDED AND RESTATED BYLAWS – EFFECTIVE JUNE 14, 2024 ARTICLE I: SHAREHOLDERS Section 1. Annual Meeting. Annual meetings of the shareholders shall be held each year within the fiscal year following the fiscal year end of the corporation, at a date, time and location (including virtually by remote communication) determined by resolution of the Board of Directors for the purp

June 20, 2024 8-K

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

June 7, 2024 CORRESP

VIA EDGAR

VIA EDGAR June 7, 2024 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.

May 31, 2024 EX-1.1

At The Market Offering Agreement between Ainos, Inc. and H.C. Wainwright & Co., LLC

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT May 31, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Ainos, Inc., a corporation organized under the laws of Texas (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement and a

May 31, 2024 S-3

As filed with the Securities and Exchange Commission on May 31, 2024

As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.

May 31, 2024 EX-4.1

Form of Indenture relating to the issuance from time to time in one or more series of debentures, notes, bonds or other evidences of indebtedness

Exhibit 4.1 AINOS, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2024 DEBT SECURITIES AINOS, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2024 Section of Trust Indenture Act of 1939 Section(s) of Indenture § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 § 311(a) 613 (b) 613 (c) Not Applicable § 312(a) 701,

May 31, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ainos, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee  Calculation  Rule Amount  Registered  (1)(2) Proposed Maximum Aggregate Offering Price Per Unit (1)(2) Maximum Aggregate Offering Price (3) Fee Rate Amount of  Registration Fee (3) Equity Com

May 13, 2024 EX-99.1

Ainos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy

Exhibit 99.1 Ainos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, May 13, 2024 /Accesswire/ — Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified healthcare company focused on the dev

May 13, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-41461 AINOS, INC. (E

May 13, 2024 8-K

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

May 8, 2024 SC 13D

AIMD / Ainos, Inc. / ADVANCED SEMICONDUCTOR ENGINEERING INC - FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ainos, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00902F303 (CUSIP Number) Joseph Tung Room 1901, No. 333, Section 1 Keelung Rd. Taipei, 110, Taiwan, Republic of China Tel: +886-2-6636-5678 (Name, Address

May 8, 2024 EX-1

*Joint Filing Agreement, dated May 3, 2024, by and between the Reporting Persons.

EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any amendments thereto) with respect to the Common Stock of Ainos, Inc.

May 6, 2024 EX-4.1

Voting Deed, dated as of May 3, 2024, by and among Ainos, Inc., a Cayman Islands company, and ASE Test, Inc.

Exhibit 4.1 VOTING DEED THIS VOTING DEED (this “DEED”) is dated as of May 3, 2024, by and among AINOS INC., a Cayman Islands company (“Ainos KY”), and ASE TEST, INC. (“Stockholder”). WHEREAS Stockholder is a stockholder of Ainos, Inc., a Texas corporation (the “Company”); WHEREAS the Company is currently traded on NASDAQ under the stock symbol “AIMD.” NOW THEREFORE, the parties, intending to be le

May 6, 2024 SC 13D/A

AIMD / Ainos, Inc. / AMARILLO BIOSCIENCES INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Ainos, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District New Taipei Cit

May 6, 2024 EX-4.3

Common Stock Warrant, dated as of May 3, 2024, issued by Ainos, Inc. to ASE Test, Inc.

Exhibit 4.3 AINOS, INC. COMMON STOCK WARRANT THIS COMMON STOCK WARRANT AND ANY SECURITIES ISSUABLE UPON THE EXERCISE OF THIS COMMON STOCK WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS THEY HAVE BEEN REGISTERED UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT. Issue Date: May 3, 20

May 6, 2024 EX-4.2

Convertible Promissory Note, dated as of May 3, 2024, issued by Ainos, Inc. in favor of ASE Test, Inc. in the principal amount of US$9,000,000.

Exhibit 4.2 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ISSUED PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSO

May 6, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

May 6, 2024 EX-10.1

Convertible Note and Warrant Purchase Agreement, dated May 3, 2024, by and between Ainos, Inc. and ASE Test, Inc.

Exhibit 10.1 CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT This Convertible Note and Warrant Purchase Agreement (the “Agreement”) is made as of May 3, 2024, by and between Ainos, Inc., a Texas corporation (the “Company”), and ASE TEST, INC., a company incorporated under the laws of the Republic of China, Taiwan (the “Purchaser”). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to th

April 12, 2024 CORRESP

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 April 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 (File No. 333-278556) CIK: 0001014763 Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amende

April 8, 2024 S-1

As filed with the Securities and Exchange Commission on April 8, 2024

As filed with the Securities and Exchange Commission on April 8, 2024 Registration No.

April 8, 2024 EX-FILING FEES

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Ainos, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees To Be Paid Equity Common Stock, par va

March 19, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

March 19, 2024 EX-10.1

Employment Agreement by and between Hsing-Liang Lee and the Company effective March 18, 2024

EXHIBIT 10.1 Mandate Agreement Date: [ March 18, 2024] Dear [ Hsin-Liang, Lee], AINOS INC. TAIWAN BRANCH (USA) (the “Company”) is very pleased to offer you appointment with the Company, as [ Chief Financial Officer (CFO)]. This Mandate Agreement (the “Agreement”) sets out the terms and conditions related to your position. 1. Effective Date / Position/ Status / Transfer (1) This Agreement will be e

March 15, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

March 11, 2024 SC 13D/A

AIMD / Ainos, Inc. / AMARILLO BIOSCIENCES INC - SC 13D/A Activist Investment

SC 13D/A 1 aimdsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Ainos, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District New

March 8, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

March 8, 2024 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-41461 AINOS, INC. (Exact name of regist

March 8, 2024 EX-97.1

Clawback policy

EXHIBIT 97.1 AINOS, INC. Clawback Policy - Adopted November 8, 2023 1.0 OVERVIEW In accordance with the applicable rules of The Nasdaq Stock Market inclusive of Rule 5608 (Recovery of Erroneously Awarded Compensation) (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Compensation Committee of the Board of Di

March 8, 2024 EX-99.1

Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing te

EXHIBIT 99.1 Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata SAN DIEGO, March 8, 2024 /Accesswire/ - Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or

March 8, 2024 EX-10.25

Employment Agreement, dated May 8, 2023, by and between the Company and Meng-Lin Sung*

EXHIBIT 10.25 Mandate Agreement Date: [ May 8, 2023] Dear [ Meng-Lin, Sung], AINOS INC. TAIWAN BRANCH (USA) (the “Company”) is very pleased to offer you appointment with the Company, as [ Chief Financial Officer (CFO)]. This Mandate Agreement (the “Agreement”) sets out the terms and conditions related to your position. 1. Effective Date / Position/ Status / Transfer (1) This Agreement will be effe

March 8, 2024 EX-9.4

Voting Agreement dated on March 7, 2024

EXHIBIT 9.4 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is dated as of March 7, 2024, by and among AINOS INC., a Cayman Islands company (“Ainos KY”), and the individuals and entities listed on Schedule A hereto (each a “Stockholder” and together the “Stockholders”). WHEREAS each Stockholder is a stockholder of Ainos, Inc., a Texas corporation (the “Company”); WHEREAS the Company is c

March 8, 2024 EX-24.1

Power of Attorney

EXHIBIT 24.1 AINOS, INC. POWER OF ATTORNEY WHEREAS, AINOS, INC., a Texas corporation (hereinafter referred to as the “Company”), proposes to file with the Securities and Exchange Commission under the provisions of the Securities Exchange Act of 1934, as amended, an annual report on Form 10-K for the period ending December 31, 2023 (the “Form 10-K”). NOW, THEREFORE, the undersigned members of the B

February 15, 2024 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-20791 AINOS, IN

February 15, 2024 EX-10.1

Ainos NISD Inabata Codevelopment Agreement - August 9, 2023, Appendix 1 and 2 redacted

EXHIBIT 10.1 APPENDIX I AND II HAVE BEEN REDACTED FROM THIS AGREEMENT PURSUANT TO SEC REGULATION S-K ITEM 601(b) BECAUSE THEY ARE BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CO-DEVELOPMENT AGREEMENT This co-development agreement (this “Agreement”) is made and entered into as of August 9, 2023 (the “Effective Date”), in Taiwan, by and betw

February 5, 2024 8-K

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

February 5, 2024 EX-99.1

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms Updated Chemistry, Manufacturing, and Controls and Stability Test

EXHIBIT 99.1 Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms Updated Chemistry, Manufacturing, and Controls and Stability Test fulfill Ainos’ development objectives Resolving the identified deficiencies will accelerate the timeline for Ainos’ other clinical trial

January 29, 2024 EX-1

Termination Agreement dated on January 26, 2024

EX-1 2 aimdex1.htm TERMINATION AGREEMENT EXHIBIT 1 Termination of Voting Agreement Effective on January 26, 2024, the undersigned hereby agree to terminate the Voting Agreement dated December 9, 2021. AINOS, INC., a Texas Corporation AINOS INC., a Cayman Islands company By: /s/Chun Hsien Tsai By: /s/Chun Hsien Tsai Chun Hsien Tsai, Chairman, President, and CEO Chun Hsien Tsai, Director By: /s/ Ste

January 29, 2024 SC 13D/A

AIMD / Ainos, Inc. / AINOS INC - SC 13D/A Activist Investment

SC 13D/A 1 aimdsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Ainos, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 00902F303 (CUSIP Number) Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District New T

January 29, 2024 EX-2

Voting Agreement dated on January 26, 2024

EX-2 3 aimdex2.htm VOTING AGREEMENT EXHIBIT 2 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is dated as of January 26, 2024, by and among AINOS INC., a Cayman Islands company (“Ainos KY”), and the individuals and entities listed on Schedule A hereto (each a “Stockholder” and together the “Stockholders”). WHEREAS each Stockholder is a stockholder of Ainos, Inc., a Texas corporation (the

January 25, 2024 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

January 25, 2024 EX-99.1

Ainos Announces $1.75 Million Follow On Funding

EXHIBIT 99.1 Ainos Announces $1.75 Million Follow On Funding The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023. Use of proceeds include to advance planned VELDONA IND preparation and AI Nose VOC platform development with Nisshinbo Micro Devices Inc. (NISD) and Taiwan Inabata Sangyo Co. (Inabata). SAN DIEGO, CA / ACCESSWIRE / Januar

January 25, 2024 EX-4.1

First Amendment, dated January 23, 2024, to Senior Secured Convertible Promissory Note dated as of September 28, 2023

EXHIBIT 4.1 FIRST AMENDMENT TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTE This First Amendment (this “Amendment”) to that certain Senior Secured Convertible Promissory Note, dated as of September 28, 2023 (the “Note”), between Ainos, Inc., a Texas corporation (the “Company”), and Lind Global Fund II L.P., a Delaware limited partnership (the “Investor”), issued pursuant to that certain Securities P

January 12, 2024 EX-10.1

English Translation of Product Development Agreement, dated on August 1, 2021

EXHIBIT 10.1 Product Development Agreement The Parties: Taiwan Carbon Nano Technology Corporation (hereinafter referred to as “Party A”) Ainos, Inc. (hereinafter referred to as “Party B”) The Agreement is hereby entered into by Party A and Party B for the purpose of product development (hereinafter referred to as “Project”) Article 1: Product Development Project: 1. Pharmaceutical related products

January 12, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

January 12, 2024 EX-10.2

English Translation of Addendum to the Product Development Agreement, dated on January 9, 2024

EXHIBIT 10.2 This is the English translation of the Chinese version. In case of discrepancies between Chinese and English versions, the Chinese version shall prevail. Addendum to the Product Development Agreement Taiwan Carbon Nano Technology Corporation (hereinafter referred to as Party A) and Ainos, Inc., its subsidiaries and branch offices (hereinafter referred to as Party B), on August 1, 2021

January 2, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 001-41461 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number)

December 22, 2023 8-K

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

December 15, 2023 S-1/A

As filed with the Securities and Exchange Commission on December 15, 2023

As filed with the Securities and Exchange Commission on December 15, 2023 Registration No.

December 14, 2023 EX-3.1

Amended and Restated Bylaws of the Company, effective November 27, 2023 (incorporated by reference to Exhibit 3.1 to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on December 14, 2023).

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF FORMATION OF AINOS, INC. Pursuant to the Texas Business Organizations Code (the “Code”), the undersigned adopts the following Certificate of Amendment to its Restated Certificate of Formation, dated April 15, 2021 (the “Certificate of Formation”). The name of the filing entity is Ainos, Inc. (the “Corporation”). This document will

December 14, 2023 CORRESP

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 December 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 (File No. 333-275971) Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Ainos, Inc

December 14, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

December 13, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

December 13, 2023 EX-99.1

Ainos,Inc. Announces Stock Consolidation

EXHIBIT 99.1 Ainos,Inc. Announces Stock Consolidation SAN DIEGO, CA, December 12, 2023 – Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos,” or the “Company”), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that, as previously authorized by its shareh

December 11, 2023 8-K

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

December 8, 2023 S-1

As filed with the Securities and Exchange Commission on December 8, 2023

As filed with the Securities and Exchange Commission on December 8, 2023 Registration No.

December 8, 2023 EX-FILING FEES

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Ainos, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees To Be Paid Equity Common Stock, par va

November 24, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

November 13, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (I

November 13, 2023 EX-99.1

Ainos Reports Third Quarter 2023 Financial Results Product Cycle Transition Approaches its Final Stages

EXHIBIT 99.1 Ainos Reports Third Quarter 2023 Financial Results Product Cycle Transition Approaches its Final Stages SAN DIEGO, November 9, 2023 /Accesswire/ - Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative

November 9, 2023 EX-10.1

Ainos NISD Inabata Codevelopment Agreement - August 9, 2023, Appendix 1 and 2 redacted

EXHIBIT 10.1 APPENDIX I AND II HAVE BEEN REDACTED FROM THIS AGREEMENT PURSUANT TO SEC REGULATION S-K ITEM 601(b) BECAUSE THEY ARE BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CO-DEVELOPMENT AGREEMENT This co-development agreement (this “Agreement”) is made and entered into as of August 9, 2023 (the “Effective Date”), in Taiwan, by and betw

November 9, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-20791 AINOS, INC.

October 27, 2023 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

October 27, 2023 DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☒ Definitive Information Statement AINOS, INC. (Name of Registrant

October 27, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

October 16, 2023 PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☐ Definitive Information Statement AINOS, INC. (Name of Registrant

September 29, 2023 EX-10.2

Securities Purchase Agreement, dated as of September 25, 2023, by and between Lind Global Fund II LP and Ainos, Inc.

EXHIBIT 10.2 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of September 25, 2023, by and between Ainos, Inc., a Texas corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”). BACKGROUND A. The board of dire

September 29, 2023 EX-10.3

Placement Agent Agreement, dated as of September 25, 2023 by and between Maxim Partners LLC and Ainos, Inc.

EXHIBIT 10.3 September 25, 2023 Mr. Chun-Hsien Tsai Chairman and Chief Executive Officer Ainos, Inc. 8880 Rio San Diego Drive, Suite 800 San Diego, CA 92108 Dear Mr. Tsai: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Ainos, Inc., a Texas corporation (the “Company”), that Maxim shall serve as the placement agent for the Compa

September 29, 2023 EX-99.1

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share

EXHIBIT 99.1 Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25 , 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos ", or the "Company"), a diversified healthcare company focused on

September 29, 2023 EX-10.1

Security Agreement, dated as of September 28, 2023, by and between Lind Global Fund II LP and Ainos, Inc.

EXHIBIT 10.1 SECURITY AGREEMENT SECURITY AGREEMENT (this "Agreement"), dated as of September 28, 2023, by and between AINOS, INC., a Texas corporation (the "Company") and LIND GLOBAL FUND II LP, a Delaware limited partnership (the "Secured Party"). WHEREAS, the Company (a) and the Secured Party have entered into that certain Securities Purchase Agreement dated as of the date hereof (as amended, am

September 29, 2023 EX-4.1

Form of Placement Agent Warrant

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

September 29, 2023 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (

September 29, 2023 EX-4.3

Common Stock Purchase Warrant to Lind Global Fund II LP

EXHIBIT 4.3 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAIL

September 29, 2023 EX-4.2

Convertible Note to Lind Global Fund II LP

EXHIBIT 4.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABL

August 22, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

August 22, 2023 EX-99.1

PROMISSORY NOTE EXTENSION AGREEMENT

EXHIBIT 99.1 PROMISSORY NOTE EXTENSION AGREEMENT This Promissory Note Agreement (the “Agreement”) is entered into this 17th day of August, 2023 (the “Effective Date”) by and between Ainos, Inc., a Texas corporation (the “Maker”), and i2China Management Group, LLC, a Delaware limited liability company, or its successors or assigns (the “Holder”). RECITALS A. The Parties entered into Non-Convertible

August 22, 2023 EX-10.1

Ainos KY Promissory Note Extension Agreement - August 17, 2023

EXHIBIT 10.1 PROMISSORY NOTE EXTENSION AGREEMENT This Promissory Note Extension Agreement (the “Agreement”) is entered into this 17TH day of August, 2023 (the “Effective Date”) by and between Ainos, Inc., a Texas corporation (the “Maker”), and Ainos, Inc., a Cayman Islands corporation, or its successors or assigns (the “Holder”). RECITALS A. The Parties entered into Non-Convertible Promissory Note

August 15, 2023 SC 13D/A

US00902F2048 / AINOS INC / AINOS INC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

August 11, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

August 11, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 0-20791 AINOS, INC. (Exac

August 11, 2023 EX-99.1

Ainos Reports Second Quarter 2023 Financial Results Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024

EXHIBIT 99.1 Ainos Reports Second Quarter 2023 Financial Results Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024 SAN DIEGO, August 11, 2023 /Accesswire/ - Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused

August 10, 2023 EX-99.1

Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption

EXHIBIT 99.1 Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry AdoptionWith Partnership, Ainos Makes Progress Towards Mission of Digitizing Smell SAN DIEGO, CA / ACCESSWIRE / August 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or

August 10, 2023 8-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

July 6, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

July 6, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS E

June 14, 2023 EX-FILING FEES

Filing Fee Table

EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ainos, Inc. (Exact Name of the Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate(2) Amount Registered(1) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(3) Equity Common Stock, par va

June 14, 2023 S-8

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact Name of Registrant as Specified in Its Charter) TEXAS 75-1974352 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8880 Rio San Diego Drive, Ste. 800 San Diego, CA (858) 869-2986 92108 (Address of Principal E

June 14, 2023 EX-4.1

Ainos, Inc. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to Ainos Inc.’s registration statement on Form S-8 filed with the SEC on June 14, 2023).

EXHIBIT 4.1 AINOS, Inc. 2023 stock Incentive Plan (As Adopted by the Board of Directors of the Company on December 31, 2022, and approved by the stockholders of the Company on February 16, 2023) 1. Purpose. The purpose of the Ainos, Inc. 2023 Stock Incentive Plan (the “Plan”) is to provide a means through which the Company, and the other members of the Company Group, may attract and retain key per

May 18, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

May 18, 2023 EX-99.1

Ainos Appoints Amanda Sung as New Chief Financial Officer Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accoun

EXHIBIT 99.1 Ainos Appoints Amanda Sung as New Chief Financial Officer Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accounting firms SAN DIEGO, CA / ACCESSWIRE / May 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medte

May 12, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 0-20791 AINOS, INC. (Exa

May 12, 2023 EX-24.1

Power of Attorney

EXHIBIT 24.1 AINOS, INC. CERTIFICATE OF CORPORATE SECRETARY I, John Junyong Lee, Corporate Secretary of Ainos, Inc., a corporate duly organized and existing under the laws of the State of Texas (the “Company”), do hereby certify that the attached is a true and correct copy of a Power of Attorney executed by all of the members of the Board of Directors of the Company and that said power of attorney

April 11, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

April 11, 2023 EX-16.1

Letter from PWR CPA LLP to the Securities and Exchange Commission dated April 10, 2023

EXHIBIT 16.1 April 10, 2023 Pao-Sheng Wei Audit Committee Chairperson Ainos, Inc. 8880 Rio San Diego Street, Suite 800 San Diego, CA 92108 Dear Mr. Pao-sheng Wei, Ainos, Inc (Ainos or ‘the Company’) informed PWR that the Company has engaged another independent auditor to replace PWR CPA, LLP effective April 10, 2023. We hereby give notice of this separation. This is also to confirm that the client

April 4, 2023 DEF 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☒ Definitive Information Statement AINOS, INC. (Name of Registrant

April 3, 2023 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [Fee Required] For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 [No Fee Required] Commission File Number 0-20791 AINOS, INC. (Exact name of registran

April 3, 2023 EX-4.1(A)

Form of Common Stock Certificate

EXHIBIT 4.1

April 3, 2023 NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 0-20791 CUSIP NUMBER: 00902F204 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra

April 3, 2023 EX-24.1

Power of Attorney

EXHIBIT 24.1 AINOS, INC. POWER OF ATTORNEY WHEREAS, AINOS, INC., a Texas corporation (hereinafter referred to as the “Company”), proposes to file with the Securities and Exchange Commission under the provisions of the Securities Exchange Act of 1934, as amended, an annual report on Form 10-K for the period ending December 31, 2022 (the “Form 10-K”). NOW, THEREFORE, the undersigned members of the B

April 3, 2023 EX-99

Ainos, Inc.

EXHIBIT 99 March 31, 2023 4:50 PM Ainos Reports Fourth Quarter and Full Year 2022 Financial Results Revenues increased by 3,832% year over year Debt ratio improved to 7% from 75% at year-end 2021 SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc.

March 14, 2023 EX-10.1(A)

AINOS, INC. CONVERTIBLE PROMISSORY NOTE

EXHIBIT 10.1(a) EXHIBIT A THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ISSUED PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR

March 14, 2023 EX-99.1

Ainos Announces US$3 Million Convertible Notes Private Placement

EXHIBIT 99.1 Ainos Announces US$3 Million Convertible Notes Private Placement SAN DIEGO, CA / ACCESSWIRE / March 13, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has entered into t

March 14, 2023 EX-2.1(B)

CONVERTIBLE NOTE PURCHASE AGREEMENT

EXHIBIT 2.1(b) CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the “Agreement”) is made as of March 13, 2023, by and between Ainos, Inc., a Texas corporation (the “Company”), and Li-Kuo Lee (the “Purchaser”). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the Purchaser, and the

March 14, 2023 EX-10.1(B)

AINOS, INC. CONVERTIBLE PROMISSORY NOTE

EXHIBIT 10.1(b) EXHIBIT A THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ISSUED PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR

March 14, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

March 14, 2023 EX-2.1(A)

Convertible Promissory Note Purchase Agreement, dated March 13, 2023, by and between the Issuer and ASE Test Taiwan in the principal amount of $2,000,000 (incorporated by reference to Exhibit 2.1(a) to the Issuer's Current Report on Form 8-K filed on March 14, 2023).

EXHIBIT 2.1(a) CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the “Agreement”) is made as of March 13, 2023, by and between Ainos, Inc., a Texas corporation (the “Company”), and ASE TEST, INC.(the “Purchaser”). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the Purchaser, and t

March 8, 2023 PRE 14C

Schedule 14-C Preliminary Information Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ☐ Definitive Information Statement AINOS, INC. (Name of Registrant

January 10, 2023 8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

November 14, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 0-20791 AINOS, INC.

October 4, 2022 EX-3.2

Amended and Restated Bylaws of the Company, effective September 28, 2022

EXHIBIT 3.2 AINOS, INC. BYLAWS ? EFFECTIVE SEPTEMBER 28 2022 ARTICLE I: SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of shareholders shall be held on the 2nd Tuesday in May of each year at 10:00 A.M. if not a legal holiday, and if a legal holiday, then on the next succeeding business day, or at such other time or on such other date as may be fixed by resolution of the Board of Direct

October 4, 2022 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number)

September 2, 2022 EX-1

Voting Agreement dated December 9, 2021 by and between the Issuer, Ainos KY, Stephen T. Chen, Virginia M. Chen, Stephen T. Chen and Virginia M. Chen as trustees of the Stephen T. Chen and Virginia M. Chen Living Trust, dated April 12, 2018, and Hung Lan Lee.

?- Schedule 13D, Amendment No. 3 EXHIBIT 1 VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?), dated December 9, 2021, is made by and among AINOS, INC. a Texas corporation (the ?Company?), Stephen T. Chen and Virginia M. Chen, individually and as Trustees of Stephen T. Chen and Virginia M. Chen Living Trust, dated April 12, 2018 (?Chen?), and Hung Lan Lee (?Lee?) (individually a ?Stockholde

September 2, 2022 SC 13D/A

AIMD / AINOS, Inc. / AINOS INC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

September 2, 2022 EX-4

Form of Promissory Notes.

EXHIBIT 4 Ainos CONVERTIBLE PROMISSORY NOTE Date: Maker: Ainos, Inc., a Texas Corporation Payee: Ainos, Inc., a Cayman Islands Corporation Place for Payment: 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108 Principal Amount: Maximum aggregate amount of $ Maturity: months, payable on , 20 Interest Rate: 1.85% per annum, on unpaid principal and accrued interest from date Conversion Price: $0

August 16, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

August 16, 2022 EX-99.1

Ainos Reports Second Quarter 2022 Financial Results

EXHIBIT 99.1 Ainos Reports Second Quarter 2022 Financial Results SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) (?Ainos?, or the ?Company?), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for th

August 15, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-20791 AINOS, INC. (Exa

August 15, 2022 EX-10.2

Convertible Promissory Note dated April [11], 2022 issued by Ainos, Inc. to ASE Test, Inc.

EXHIBIT 10.2 EXHIBIT A AINOS, INC. THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMEN

August 15, 2022 EX-10.1

Convertible Note Purchase Agreement dated as of April 11, 2022 between Ainos, Inc. and ASE Test, Inc.

EXHIBIT 10.1 CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the ?Agreement?) is made as of April 11 2022, by and between Ainos, Inc., a Texas corporation (the ?Company?), and ASE TEST, INC. (the ?Purchaser?). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the Purchaser, and the

August 12, 2022 EX-4.3

Warrant Agency Agreement dated as of August 11, 2022 by and between the Ainos, Inc. and American Stock Transfer & Trust Company, LLC.

EXHIBIT 4.3 AINOS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of August 11, 2022 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August 11, 2022 (?Agreement?), between Ainos, Inc., a corporation organized under the laws of the State of Texas (the ?Company?), and American Stock Transfer & Trust Company (the ?Warrant Agent?).

August 12, 2022 EX-1.1

Underwriting Agreement, dated August 8, 2022, by and between Ainos, Inc. and Maxim Group LLC.

EXHIBIT 1.1 AINOS, INC. UNDERWRITING AGREEMENT August 8, 2022 MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, NY 10022 As Representative of the Underwriters named on Schedule I hereto Ladies and Gentlemen: The undersigned, Ainos, Inc., a Texas corporation (the ?Company?), hereby confirms its agreement (this ?Agreement?) to issue and sell to the underwriter or underwriters, as the case may be

August 12, 2022 EX-3.1

Certificate of Amendment to the Restated Certificate of Formation, dated August 8, 2022

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF FORMATION OF AINOS, INC. Pursuant to the Texas Business Organizations Code (the ?Code?), the undersigned adopts the following Certificate of Amendment to its Restated Certificate of Formation, dated April 15, 2021 (the ?Certificate of Formation?). The name of the filing entity is Ainos, Inc. (the ?Corporation?). This document beco

August 12, 2022 EX-99.1

Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

EXHIBIT 99.1 Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split SAN DIEGO, CA / ACCESSWIRE / August 8, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today annou

August 12, 2022 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):August 8, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

August 12, 2022 EX-4.2

COMMON STOCK PURCHASE WARRANT AINOS, INC.

EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT AINOS, INC. Warrant Shares: 897,000 Initial Exercise Date: August 11, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (t

August 12, 2022 EX-99.2

Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

EXHIBIT 99.2 Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, toda

August 10, 2022 424B4

780,000 Units each consisting of One Share of Common Stock One Warrant to purchase One Share of Common Stock

424B4 1 aimd424b4.htm 424B4 Filed pursuant to Rule 424(b)(4) Registration No. 333-264527 PROSPECTUS 780,000 Units each consisting of One Share of Common Stock and One Warrant to purchase One Share of Common Stock This prospectus relates to the public offering of units (“Units”), with each Unit consisting of one share of the Company’s common stock, par value $0.01 per share, and one warrant (the “W

August 4, 2022 CORRESP

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 August 4, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 (File No. 333-264527) Ladies and Gentlemen: On August 2, 2022, Ainos, Inc. (the ?Company?) requested acceleration of the effectiveness of its R

August 4, 2022 CORRESP

August 4, 2022

CORRESP 1 filename1.htm August 4, 2022 Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 File No. 333-264527 VIA EDGAR Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on August 2, 2022, in which we, Maxim Group LLC, as representative of the underwriters, joined the Company’s reques

August 4, 2022 CORRESP

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

CORRESP 1 filename1.htm Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 August 4, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 (File No. 333-264527) Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, a

August 2, 2022 CORRESP

August 2, 2022

CORRESP 1 filename1.htm August 2, 2022 Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 File No. 333-264527 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as representat

August 2, 2022 EX-4.1

Form of Warrant

EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT AINOS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial Exercise Date?)

August 2, 2022 S-1/A

December 31,

As filed with the Securities and Exchange Commission on August 2, 2022 Registration No.

August 2, 2022 EX-3.2

Form of Certificate of Amendment to the Restated Certificate of Formation, to be effective upon completion of this offering

EXHIBIT 3.2 [FORM OF] CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF FORMATION OF AINOS, INC. Pursuant to the Texas Business Organizations Code (the ?Code?), the undersigned adopts the following Certificate of Amendment to its Restated Certificate of Formation, dated April 15, 2021 (the ?Certificate of Formation?). The name of the filing entity is Ainos, Inc. (the ?Corporation?). This doc

August 2, 2022 EX-4.3

Form of Warrant Agency Agreement

EXHIBIT 4.3 AINOS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of , 2022 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 (?Agreement?), between Ainos, Inc., a corporation organized under the laws of the State of Texas (the ?Company?), and American Stock Transfer & Trust Company (the ?Warrant Agent?). W I T N E S S E T

August 2, 2022 EX-1.1

Form of Representative’s Warrant (included in Exhibit 1.1).

EX-1.1 2 aimdex11.htm FORM OF UNDERWRITING AGREEMENT EXHIBIT 1.1 AINOS, INC. UNDERWRITING AGREEMENT [], 2022 MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, NY 10022 As Representative of the Underwriters named on Schedule I hereto Ladies and Gentlemen: The undersigned, Ainos, Inc., a Texas corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the

August 2, 2022 CORRESP

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108

Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 August 2, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ainos, Inc. Registration Statement on Form S-1 (File No. 333-264527) Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Ainos, Inc.,

August 1, 2022 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ainos, Inc. (Exact name of registrant as specified in its charter) Texas 75-1974352 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 8880 Rio San D

July 27, 2022 S-1/A

As filed with the Securities and Exchange Commission on July 27, 2022

As filed with the Securities and Exchange Commission on July 27, 2022 Registration No.

July 25, 2022 S-1/A

As filed with the Securities and Exchange Commission on July 25, 2022

As filed with the Securities and Exchange Commission on July 25, 2022 Registration No.

July 8, 2022 S-1/A

As filed with the Securities and Exchange Commission on July 8, 2022

As filed with the Securities and Exchange Commission on July 8, 2022 Registration No.

July 7, 2022 EX-FILING FEES

Filing Fee Table

EX-FILING FEES 4 aimdex107.htm CALCULATION OF FILING EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ainos, Inc. (Exact Name of the Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate(2) Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amou

July 7, 2022 S-8

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact Name of Registrant as Specified in Its Charter) TEXAS 75-1974352 (State or other jurisdiction of Identification No.) (I.R.S. Employer incorporation or organization) 8880 Rio San Diego Drive, Ste. 800 San Diego, CA (858) 869-2986 92108 (Address of Principal E

July 7, 2022 S-8

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AINOS, INC. (Exact Name of Registrant as Specified in Its Charter) TEXAS 75-1974352 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8880 Rio San Diego Drive, Ste. 800 San Diego, CA (858) 869-2986 92108 (Address of Principal E

July 7, 2022 EX-FILING FEES

Filing Fee Table

EX-FILING FEES 4 aimdex107.htm FILING FEE EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ainos, Inc. (Exact Name of the Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate(2) Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Regis

June 24, 2022 EX-10.1

Ainos, Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to Ainos Inc.’s registration statement on Form S-8 filed with the SEC on July 7, 2022).

EXHIBIT 10.1 AINOS, Inc. 2021 Stock Incentive Plan (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on May 16, 2022) 1. Purpose. The purpose of the Ainos, Inc. 2021 Stock Incentive Plan is to provide a means through which the Company, and the other members of the Company Group, may attract and retain key personnel, and to prov

June 24, 2022 EX-10.2

Ainos, Inc. 2021 Employee Stock Purchase Plan

EXHIBIT 10.2 Ainos, Inc. 2021 EMPLOYEE STOCK PURCHASE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on May 16, 2022) 1. Definitions. (a) ?Administrator? means the Committee or, subject to Applicable Law, a subcommittee of the Committee or one or more of the Company?s officers or management team appointed by the Board o

June 24, 2022 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

June 17, 2022 8-K/A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

June 16, 2022 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

June 1, 2022 DEF 14C

2021 Employee Stock Purchase Plan *

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c?101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ? Definitive Information Statement AINOS, INC. (Name of Registrant

May 18, 2022 PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c?101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) ? Definitive Information Statement AINOS, INC. (Name of Registrant

May 16, 2022 EX-24.1

Power of Attorney by Board of Directors

EX-24.1 2 aimdex241.htm POWER OF ATTORNEY EXHIBIT 24.1 AINOS, INC. CERTIFICATE OF CORPORATE SECRETARY I, John Junyong Lee, Corporate Secretary of Ainos, Inc., a corporate duly organized and existing under the laws of the State of Texas (the “Company”), do hereby certify that the attached is a true and correct copy of a Power of Attorney executed by all of the members of the Board of Directors of t

May 16, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-20791 AINOS, INC. (Ex

April 28, 2022 EX-3.2

Amended and Restated Bylaws of the Company, effective August 20, 2021

EXHIBIT 3.2 AINOS, INC. BYLAWS ? EFFECTIVE AUGUST 20, 2021 ARTICLE I: SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of shareholders shall be held on the 2nd Tuesday in May of each year at 10:00 A.M. if not a legal holiday, and if a legal holiday, then on the next succeeding business day, or at such other time or on such other date as may be fixed by resolution of the Board of Director

April 28, 2022 EX-FILING FEES

Filing Fee Table

EX-FILING FEES 3 aimdex107.htm FEE TABLE EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ainos, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra

April 28, 2022 S-1

As filed with the Securities and Exchange Commission on April 28, 2022

As filed with the Securities and Exchange Commission on April 28, 2022 Registration No.

April 15, 2022 EX-2.1

Form of Convertible Note Purchase Agreement

EXHIBIT 2.1 CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the ?Agreement?) is made as of , by and between Ainos, Inc. (formerly known as Amarillo Biosciences, Inc.), a Texas corporation (the ?Company?), and (the ?Purchaser?). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the

April 15, 2022 EX-10.1

Form of Convertible Promissory Note

EXHIBIT 10.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ISSUED PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERS

April 15, 2022 10-K/A

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [Fee Required] For the Fiscal Year Ended December 31, 2021 ? Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 [No Fee Required] Commission File Number 0-20791 AINOS, INC. (Exa

April 15, 2022 EX-10.(VI)

This document is the English translation of the Chinese version. In case of discrepancies between Chinese and English versions, the Chinese version shall prevail. Oral Antiviral Therapy Development and Sales Agreement

EXHIBIT 10 (vi) Appendix 4 This document is the English translation of the Chinese version.

April 15, 2022 EX-99.(I)

Application No.

EXHIBIT 99(i) # Patent name in English Country Status Application No. Patent No. Type Application Date Issued Date Expiry Date Patent Term 1 A GAS SENSOR AND MANUFACTURE METHODTHEREOF Taiwan Approved 104141667 I565944 Invention 2015/12/11 2017/01/11 2035/12/10 20 2 GAS DETECTOR Taiwan Approved 105305596 D183554 Design 2016/09/22 2017/06/11 2031/09/21 15 3 MEDICAL VENTILATOR CAPABLE OF ANALYZINGINF

April 15, 2022 EX-10.(XIII)

AINOS, INC. 2021 STOCK INCENTIVE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [•], 2021)

EXHIBIT 10(xiii) AINOS, INC. 2021 STOCK INCENTIVE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [?], 2021) 1. Purpose. The purpose of the Ainos, Inc. 2021 Stock Incentive Plan is to provide a means through which the Company, and the other members of the Company Group, may attract and retain key personnel, and to pro

April 15, 2022 EX-24.(I)

POWER OF ATTORNEY

EXHIBIT 24(i) POWER OF ATTORNEY WHEREAS, AINOS, INC., a Texas corporation (hereinafter referred to as the ?Company?), proposes to file with the Securities and Exchange Commission under the provisions of the Securities Exchange Act of 1934, as amended, an annual report on Form 10-K for the fiscal year ended December 31, 2021 (the ?2021 Form 10-K?). NOW, THEREFORE, the undersigned hereby appoints Ch

April 15, 2022 EX-10.(III)

SALES AND MARKETING AGREEMENT

EXHIBIT 10(iii) SALES AND MARKETING AGREEMENT THIS SALES AND MARKETING AGREEMENT (?Agreement?) is made on June 14, 2021 (?Effective Date?) by and between Ainos, Inc.

April 15, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

April 15, 2022 EX-10.(XII)

Ainos, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [•], 2021)

EXHIBIT 10(xii) Ainos, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [?], 2021) 1. Definitions. (a) ?Administrator? means the Committee or, subject to Applicable Law, a subcommittee of the Committee or one or more of the Company?s officers or management team appointed by the Board o

April 15, 2022 EX-10.(XIV)

Non-Employee Director Compensation Policy

EXHIBIT 10(xiv) AINOS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 6, 2021 Each member of the Board of Directors (the ?Board?) of Ainos, Inc. (the ?Company?) who is not an employee of the Company or any of subsidiaries (each such member, a ?Non-Employee Director?) will receive the compensation described in this Director Compensation Policy (the ?Non-Em

April 4, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

April 4, 2022 EX-10.1

Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on April 4, 2022).

EXHIBIT 10.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ISSUED PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERS

April 4, 2022 EX-2.1

Form of Convertible Note Purchase Agreement, between the Company and the purchasers party thereto (incorporated by reference to Exhibit 2.1 to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on April 4, 2022).

EXHIBIT 2.1 CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the ?Agreement?) is made as of , by and between Ainos, Inc. (formerly known as Amarillo Biosciences, Inc.), a Texas corporation (the ?Company?), and (the ?Purchaser?). 1. Purchase and Sale; Closing. 1.1 Purchase of Note. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the

March 21, 2022 EX-10.(XIII)

2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to Ainos Inc.’s Annual Report on Form 10-K filed with the SEC on March 21, 2022).

EXHIBIT 10(xiii) AINOS, INC. 2021 STOCK INCENTIVE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [?], 2021) 1. Purpose. The purpose of the Ainos, Inc. 2021 Stock Incentive Plan is to provide a means through which the Company, and the other members of the Company Group, may attract and retain key personnel, and to pro

March 21, 2022 EX-10.(XIV)

Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.14 to Ainos Inc.’s Annual Report on Form 10-K filed with the SEC on March 21, 2022).

EXHIBIT 10(xiv) AINOS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 6, 2021 Each member of the Board of Directors (the ?Board?) of Ainos, Inc. (the ?Company?) who is not an employee of the Company or any of subsidiaries (each such member, a ?Non-Employee Director?) will receive the compensation described in this Director Compensation Policy (the ?Non-Em

March 21, 2022 EX-10.(XII)

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.12 to Ainos Inc.’s Annual Report on Form 10-K filed with the SEC on March 21, 2022).

EXHIBIT 10(xii) Ainos, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (As Adopted by the Board of Directors of the Company on October 6, 2021, and approved by the stockholders of the Company on [?], 2021) 1. Definitions. (a) ?Administrator? means the Committee or, subject to Applicable Law, a subcommittee of the Committee or one or more of the Company?s officers or management team appointed by the Board o

March 21, 2022 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [Fee Required] For the Fiscal Year Ended December 31, 2021 ? Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 [No Fee Required] Commission File Number 0-20791 AINOS, INC. (Exact name of registran

March 21, 2022 EX-10.(VI)

Oral Antiviral Therapy Development and Sales Agreement by and between Ainos, Inc. and Innopharmax, Inc., dated as of December 7, 2021 (incorporated by reference to Exhibit 10.7 to Ainos Inc.’s Annual Report on Form 10-K filed with the SEC on March 21, 2022).

EXHIBIT 10 (vi) Appendix 4 This document is the English translation of the Chinese version.

March 21, 2022 EX-10.(III)

Sales and Marketing Agreement, dated as of June 14, 2021 (incorporated by reference to Exhibit 10.3 to Ainos Inc.’s Annual Report on Form 10-K filed with the SEC on March 21, 2022).

EXHIBIT 10(iii) SALES AND MARKETING AGREEMENT THIS SALES AND MARKETING AGREEMENT (?Agreement?) is made on June 14, 2021 (?Effective Date?) by and between Ainos, Inc.

March 17, 2022 EX-10.(I)

Non-Convertible Promissory Note, dated March 4, 2022, issued by the Company to Ainos Inc. (incorporated by reference to Exhibit 10(i) to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on March 17, 2022).

EXHIBIT 10(I) THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS.

March 17, 2022 EX-10.(IV)

Employment Agreement, dated March 17, 2022, by and between the Company and Hui-Lan Wu (incorporated by reference to Exhibit 10(iv) to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on March 17, 2022).

EXHIBIT 10(IV) Mandate Agreement ???? RECITALS A. Employee was appointed by the Board of the Directors (the ?Board?) of the Company as Chief Financial Officer on August 11, 2021; B. The Company issued an Offer Letter dated September 29, 2021 offering certain employment terms and conditions, salary, bonuses, and benefits effective as of August 11, 2021 and said Offer Letter was approved by the Boar

March 17, 2022 EX-10.(V)

Employment Agreement, dated March 17, 2022, by and between the Company and Chih-Heng Jack Lu (incorporated by reference to Exhibit 10(v) to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on March 17, 2022).

EXHIBIT 10(V) Employment Agreement ???? RECITALS A. Employee was appointed by the Board of the Directors (the ?Board?) of the Company as Corporate Secretary on August 11, 2021; B. The Company issued an Offer Letter dated September 29, 2021 offering certain employment terms and conditions, salary, bonuses, and benefits effective as of October 1, 2021; C. This Employment Agreement is intended to inc

March 17, 2022 EX-10.(III)

Employment Agreement, dated March 17, 2022, by and between the Company and Chun-Hsien Tsai (incorporated by reference to Exhibit 10(iii) to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on March 17, 2022).

EXHIBIT 10(III) Mandate Agreement ???? RECITALS A. Employee was appointed by the Board of the Directors (the ?Board?) of the Company as Chief Executive Officer on April 15, 2021; B. The Company issued an Offer Letter dated September 29, 2021 offering certain employment terms and conditions, salary, bonuses, and benefits effective as of April 15, 2021 and said Offer Letter was approved by the Board

March 17, 2022 EX-10.(II)

Note Extension Agreement, dated March 17, 2022, between the Company and Ainos Inc. (incorporated by reference to Exhibit 10(ii) to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on March 17, 2022).

EXHIBIT 10(II) PROMISSORY NOTE EXTENSION AGREEMENT Total Principal Amount: $3,000,000 This Promissory Note Extension Agreement, hereinafter referred to as ?Extension Agreement,? entered into this 17TH day of March, 2022, by and between Ainos, Inc.

March 17, 2022 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS

March 8, 2022 SC 13D/A

AIMD / AINOS, Inc. / AINOS INC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

February 3, 2022 EX-10.1

Convertible Promissory Note, dated as of January 30, 2022, issued by the Company to Ainos Inc. (incorporated by reference to Exhibit 10.1 to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on February 3, 2022).

EXHIBIT 10.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR A

February 3, 2022 EX-2.1

Amended and Restated Asset Purchase Agreement, dated as of January 29, 2022, between Ainos Inc. and Ainos, Inc. (incorporated by reference to Exhibit 2.1 to Ainos Inc.’s Current Report on Form 8-K filed with the SEC on February 3, 2022).

EXHIBIT 2.1 AMENDED AND RESTATED ASSET PURCHASE AGREEMENT This Amended and Restated Asset Purchase Agreement (the ?Agreement?) is made as of this 29th day of January, 2022 (the ?Effective Date?), by and between Ainos, Inc. (?Buyer?), a Texas corporation, with an address of 8880 Rio San Diego Drive, Suite 800 San Diego, CA 92108, and Ainos, Inc. (?Seller?), a Cayman Islands corporation, with an add

February 3, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2022 AINOS, INC (Exact name of registrant as specified in its charter) Texas 0-20791 75-1974352 (State or other Jurisdiction of Incorporation) (Commission File Number) (IR

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista